萨库比特里尔-瓦尔萨坦降低了透析患者的血压:一个随机控制的多中心研究
Li Lin1, Weijing Bian2, Qun Luo3
1Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Kidney diseases (Basel, Switzerland)
|April 21, 2025
概括
在透析患者,特别是血液透析患者中,萨库比特利-瓦尔萨坦 (ARNI) 显著降低了血压,远高于伊尔贝沙坦 (ARB). 这两种治疗都显示了可比的安全性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压是末期病患者的常见和严重并发症.
- 失控的血压会增加透析患者的心血管风险.
研究的目的:
- 为了比较sacubitril-valsartan (ARNI) 与irbesartan (ARB) 在透析患者的高血压管理中的有效性和安全性.
- 评估这些治疗对血压和N-终端前脑性尿素 (NT-proBNP) 水平的影响.
主要方法:
- 一项涉及10家医院的随机,受控,多中心研究.
- 参与者接受了12个月的sacubitril-valsartan (ARNI) 或irbesartan (ARB) 治疗.
- 通过办公室和24小时门诊血压读数以及NT-proBNP水平来评估有效性.
主要成果:
- 与伊尔贝萨坦 (ARB) 相比,萨库比特里尔-瓦尔萨坦 (ARNI) 显示了与伊尔贝萨坦 (ARB) 相比,系统血压的显著降低 (-10.4 与 -4.6 mm Hg 相比,p = 0.003).
- 与ARB相比,血液透析患者在ARNI的治疗中经历了较大的血压降低 (-15.9/2.4 vs -6.6/1.1 mm Hg,p < 0.05).
- 在腹腔透析患者中没有观察到血压降低的显著差异 (p = 0.087).
结论:
- 在降低透析患者的血压方面,ARNI比ARB更有效,特别是在透析患者中.
- 萨库比特里尔-瓦尔萨坦和伊尔贝萨坦均表现出可接受和可比的安全性概况,在不良事件或高血症方面没有显著差异.
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
572
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
572
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
376
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
376
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
530
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
530
01:25Antihypertensive Drugs: Direct Renin Inhibitors
440
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
440
01:22Heart Failure Drugs: Diuretics
282
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
282
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305